• Mashup Score: 0
    Point-of-care CAR T-cells - 3 year(s) ago

    Marcos de Lima, MD, UH Cleveland Medical Center, Cleveland, OH, discusses the significance of point-of-care CAR T-cell therapies. This interview…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Point-of-care #CART cell therapy with @DrMarcosdelima of @UHhospitals: https://t.co/MjrPPHrc3b @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #ImmunoOnc #CaxTx

  • Mashup Score: 2
    Brentuximab vedotin + nivolumab in lymphoma - 3 year(s) ago

    David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses updates from a study evaluating brentuximab vedotin, an…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Brentuximab vedotin + nivolumab in #Lymphoma with @DrDavidStraus of @sloan_kettering: https://t.co/tAxZQJG1pr @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #Lymsm #Lymphoma #CaxTx #ImmunoOnc

  • Mashup Score: 1
    Next steps in multiple myeloma - 3 year(s) ago

    Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses next steps in the treatment and management…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Next steps in #MultipleMyeloma with @SagarLonialMD of @EmoryMedicine: https://t.co/bSVRiZtQv5 @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #MMSM #Myeloma

  • Mashup Score: 0
    Updates from the German CLL Study Group - 3 year(s) ago

    Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, updates us on the latest news from the German CLL Study…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Updates from the German #CLL Study Group with @HallekMichael of @UniCologne: https://t.co/0XrQKF1nI7 @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #Leusm #Leukemia #CLLsm

  • Mashup Score: 2
    Management of adult T-ALL - 3 year(s) ago

    Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the management of patients with T-cell…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Management of adult T-#ALL with @NitinJainMD of @MDAndersonNews: https://t.co/iRfbOzhELo @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #ImmunoOnc #Leusm #Leukemia #ALLsm #CaxTx

  • Mashup Score: 0
    Magrolimab in TP53 mutated AML and MDS - 3 year(s) ago

    David Sallman, MD, of H. Lee Moffitt Cancer Center, Tampa, FL, outlines the use of magrolimab in TP53 mutated acute…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Magrolimab in TP53 mutated #AML and #MDS with David Sallman of @MoffittNews: https://t.co/gmYEOsUdBh @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #Leusm #Leukemia #AMLsm #MDSsm

  • Mashup Score: 1
    Treating highly relapsed/refractory CLL - 3 year(s) ago

    Michael Hallek, MD, of the University Hospital of Cologne, Cologne, Germany, outlines treatment options for relapsed/refractory patients with chronic lymphocytic…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Treating highly relapsed/refractory #CLL w/ @HallekMichael of @UKKoeln: https://t.co/9EKwLA2q9R @SocietyofHemOnc #SOHO2020 #HemOnc #Leusm #CLLsm #Leukemia #OncoAlert @OncoAlert https://t.co/QtFVDprxXi

  • Mashup Score: 0
    Next questions in AML - 3 year(s) ago

    Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, explores the next questions in acute myeloid leukemia…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Next questions in #AML w/@Dr_AmerZeidan of @Yale: https://t.co/b7YtHMDK7N @SocietyofHemOnc #SOHO2020 #HemOnc #Leusm #AMLsm #Leukemia #OncoAlert @OncoAlert https://t.co/nJNaa1g358

  • Mashup Score: 0
    Gilteritinib in R/R AML - 3 year(s) ago

    Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of gilteritinib, a tyrosine…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: #Gilteritinib in R/R AML w/ @Daver_Leukemia of @LeukemiaMDA: https://t.co/lz0tNcWTA6 @SocietyofHemOnc #SOHO2020 #HemOnc #Leusm #AMLsm #Leukemia #OncoAlert @OncoAlert

Load More